

## Alerts and Recalls

### Generic Name (Trade Name—Company)

May 14, 2018

### **Piperacillin and tazobactam for injection, 3.375 g vials**

**(No trade name—AuroMedics Pharma)**

**Recalled product contains glass particulate matter**

### Uses/Notes

AuroMedics Pharma is voluntarily [recalling](#) two lots (PP0317061-A, exp. Aug 2019, and PP0317049-A, exp. Aug 2019) of piperacillin and tazobactam for injection, 3.375 g (piperacillin sodium equivalent to 3 g of piperacillin and tazobactam sodium equivalent to 0.375 g of tazobactam) to the hospital level. Each single-dose vial contains 7.05 mEq (162 mg) of sodium.

The medication is packaged in a carton containing 10 single-dose vials (NDC: 55150-120-30).

The products have been found to contain particulate matter, visible only after reconstitution, that was confirmed to be glass within the vial.

Administration of a glass particulate, if present in I.V. drug, may result in local irritation or swelling in response to the foreign material. More serious potential outcomes would include blockage and clotting in blood vessels, which may be life-threatening.

Piperacillin and tazobactam for injection is used for treatment of patients with moderate to severe infections caused by susceptible isolates of the designated bacteria in intra-abdominal, skin and skin structure, and female pelvic infections, as well as community acquired and nosocomial pneumonia.

AuroMedics Pharma is notifying its distributors and customers by recall letters and is arranging for return and replacement of all recalled product.

To date, AuroMedics Pharma has not received reports of any adverse events or identifiable safety concerns attributed to use of the product from these lots.

### Source URL:

<http://personify.pharmacist.com/alerts-and-recalls/recalled-product-contains-glass-particulate-matter>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily

represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.